Voyager Therapeutics Statistics Share Statistics Voyager Therapeutics has 55.34M
shares outstanding. The number of shares has increased by 1.47%
in one year.
Shares Outstanding 55.34M Shares Change (YoY) 1.47% Shares Change (QoQ) 0.23% Owned by Institutions (%) 52.74% Shares Floating 45.29M Failed to Deliver (FTD) Shares 8 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 3.13M, so 5.65% of the outstanding
shares have been sold short.
Short Interest 3.13M Short % of Shares Out 5.65% Short % of Float 6.74% Short Ratio (days to cover) 4.77
Valuation Ratios The PE ratio is -5.03 and the forward
PE ratio is -2.38.
Voyager Therapeutics's PEG ratio is
0.04.
PE Ratio -5.03 Forward PE -2.38 PS Ratio 4.09 Forward PS 2.7 PB Ratio 1.09 P/FCF Ratio -17.36 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Voyager Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.56,
with a Debt / Equity ratio of 0.15.
Current Ratio 5.56 Quick Ratio 5.56 Debt / Equity 0.15 Debt / EBITDA -0.56 Debt / FCF -2.32 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $465.12K Profits Per Employee $-377.92K Employee Count 172 Asset Turnover 0.2 Inventory Turnover n/a
Taxes Income Tax 665K Effective Tax Rate -1.03%
Stock Price Statistics The stock price has increased by -53.54% in the
last 52 weeks. The beta is 0.9, so Voyager Therapeutics's
price volatility has been higher than the market average.
Beta 0.9 52-Week Price Change -53.54% 50-Day Moving Average 3.22 200-Day Moving Average 4.43 Relative Strength Index (RSI) 47.07 Average Volume (20 Days) 741,279
Income Statement In the last 12 months, Voyager Therapeutics had revenue of 80M
and earned -65M
in profits. Earnings per share was -1.13.
Revenue 80M Gross Profit 80M Operating Income -83.29M Net Income -65M EBITDA -78.56M EBIT -83.29M Earnings Per Share (EPS) -1.13
Full Income Statement Balance Sheet The company has 71.37M in cash and 43.73M in
debt, giving a net cash position of 27.64M.
Cash & Cash Equivalents 71.37M Total Debt 43.73M Net Cash 27.64M Retained Earnings -326.18M Total Assets 322.1M Working Capital 185.91M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -15.31M
and capital expenditures -3.52M, giving a free cash flow of -18.83M.
Operating Cash Flow -15.31M Capital Expenditures -3.52M Free Cash Flow -18.83M FCF Per Share -0.33
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -104.11% and -81.25%.
Gross Margin 100% Operating Margin -104.11% Pretax Margin -80.42% Profit Margin -81.25% EBITDA Margin -98.19% EBIT Margin -104.11% FCF Margin -23.54%
